| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target ...
Piper Sandler analyst Matt O'Brien maintains TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price targ...
TransMedics Group (NASDAQ:TMDX) raises FY2025 sales outlook from $585.000 million-$605.000 million to $595.000 million-$605.000...
TransMedics Gr (NASDAQ:TMDX) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.35 ...
Needham analyst Mike Matson upgrades TransMedics Group (NASDAQ:TMDX) from Hold to Buy and announces $148 price target.
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and maintains $142 price tar...